|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61P 7/02 | (2006.01) |
| A61K 9/20 | (2006.01) | ||
| A61K 9/16 | (2006.01) | ||
| A61K 31/4545 | (2006.01) |
| (11) | Number of the document | 2442791 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10727611.5 |
| Date of filing the European patent application | 2010-06-15 | |
| (97) | Date of publication of the European application | 2012-04-25 |
| (45) | Date of publication and mention of the grant of the patent | 2019-11-27 |
| (46) | Date of publication of the claims translation | 2020-02-25 |
| (86) | Number | PCT/US2010/038660 |
| Date | 2010-06-15 |
| (87) | Number | WO 2010/147978 |
| Date | 2010-12-23 |
| (30) | Number | Date | Country code |
| 187442 P | 2009-06-16 | US |
| (72) |
NAUSE, Richard, G., US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
Bristol-Myers Squibb Holdings Ireland Unlimited Company, Hinterbergstrasse 16, 6312 Steinhausen, CH |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Apiksabano vaisto formos |
| DOSAGE FORMS OF APIXABAN |
| Payment date | Validity (years) | Amount | |
| 2025-05-05 | 16 | 347.00 EUR |
| 2026-06-15 |